Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
The report details the trend, potential and market size of Cancer mTOR Inhibitors market, and analyzes the current situation and prospects of the market from both qualitative and quantitative aspects, which can be roughly divided into three parts.
The first part (Chapter1-7) mainly covers the qualitative analysis of Cancer mTOR Inhibitorsmarket, defines the market attractiveness level of Cancer mTOR Inhibitors market through Porter's Five Forces Analysis, and summarizes the different factors in the overall environment through PEST analysis. Understand the distribution of industrial chain value in each link of industrial chain through the analysis of industrial chain structure. Thus estimate the market space of each link.
The second part (Chapter8-12), based on the segmentation of Cancer mTOR Inhibitors industry, describes the types of Cancer mTOR Inhibitors market, the applications of major players and the market size, and deeply analyzes the current situation of the global Cancer mTOR Inhibitors market and the development prospects and opportunities of Cancer mTOR Inhibitors industry.
The third part (Chapter14-15) includes the market positions of the major players and information on the market participants, which will help you gain a comprehensive understanding of the current competitive situation and potential growth opportunities in the market.
As COVID-19 continues to impact the global economy in 2022, the report also considers the short - and long-term impacts of COVID-19 on the global Cancer mTOR Inhibitors market in Chapter 13.
By Player:
HEC Pharm
Takeda
Adimab
Intellikine
Abraxis BioScience
GlaxoSmithKline
Semafore Pharmaceuticals
Wyeth
Oneness Biotech
Eli Lilly
Celator Pharmaceuticals
Novartis
Exelixis
Celgene Corporation
PIQUR Therapeutics
By Type:
Afinitor/Votubia
Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
Torisel (Temsirolimus)
Evertor andndash
By End-User:
Breast Cancer
Hematological Malignancy
Neuroendocrine Tumors
Hepatocellular Carcinoma
Glioblastoma
By Geography:
-
United States
-
Europe
-
China
-
Japan
-
India
-
South Korea
TABLE OF CONTENT
1 Introduction
-
1.1 Market Definition
-
1.2 Market Segment Analysis
-
1.3 Market Size 2022
-
1.4 Cancer mTOR Inhibitors Market Outlook: Forecast for 2022 - 2028
-
1.5 Pricing Analysis
2 Executive Summary
3 Cancer mTOR Inhibitors Market Lineage Outlook
-
3.1 Parent Market Outlook
-
3.2 Related/Ancillary Market Outlook
-
3.3 Penetration & Growth Prospect Mapping, 2022
4 Market Analysis Tools: Porter's Five Forces
-
4.1 Supplier Power
-
4.2 Buyer Power
-
4.3 Substitution Threat
-
4.4 Threat of New Entrants
-
4.5 Competitive Rivalry
5 Cancer mTOR Inhibitors Industry Analysis - PEST (Political & Legal, Economic, Social, and Technological)
-
5.1 Political/Legal Landscape
-
5.2 Economic Landscape
-
5.3 Social Landscape
-
5.4 Technology Landscape
6 Cancer mTOR Inhibitors Market - Value Chain Analysis
-
6.1 Industry's Value Chain Analysis
-
6.2 Product Life Cycle
-
6.3 User Perspective Analysis
7 Region and Country-wise Cancer mTOR Inhibitors Market Analysis and Outlook to 2022
-
7.1 Global Cancer mTOR Inhibitors Consumption (2017-2022)
-
7.2 United States Cancer mTOR Inhibitors Consumption (2017-2022)
-
7.3 Europe Cancer mTOR Inhibitors Consumption (2017-2022)
-
7.4 China Cancer mTOR Inhibitors Consumption (2017-2022)
-
7.5 Japan Cancer mTOR Inhibitors Consumption (2017-2022)
-
7.6 India Cancer mTOR Inhibitors Consumption (2017-2022)
-
7.7 South Korea Cancer mTOR Inhibitors Consumption (2017-2022)
8 Region and Country-wise Cancer mTOR Inhibitors Market Analysis and Outlook to 2028
-
8.1 Global Cancer mTOR Inhibitors Consumption Forecast (2022-2028)
-
8.2 United States Cancer mTOR Inhibitors Consumption Forecast (2022-2028)
-
8.3 Europe Cancer mTOR Inhibitors Consumption Forecast (2022-2028)
-
8.4 China Cancer mTOR Inhibitors Consumption Forecast (2022-2028)
-
8.5 Japan Cancer mTOR Inhibitors Consumption Forecast (2022-2028)
-
8.6 India Cancer mTOR Inhibitors Consumption Forecast (2022-2028)
-
8.7 South Korea Cancer mTOR Inhibitors Consumption Forecast (2022-2028)
9 Global Cancer mTOR Inhibitors Market Outlook by Types and Applications to 2022
-
9.1 Global Cancer mTOR Inhibitors Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Afinitor/Votubia Consumption and Growth Rate (2017-2022)
-
9.1.2 Global Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Torisel (Temsirolimus) Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Evertor andndash Consumption and Growth Rate (2017-2022)
-
9.2 Global Cancer mTOR Inhibitors Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Breast Cancer Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Hematological Malignancy Consumption and Growth Rate (2017-2022)
-
9.2.3 Global Neuroendocrine Tumors Consumption and Growth Rate (2017-2022)
-
9.2.4 Global Hepatocellular Carcinoma Consumption and Growth Rate (2017-2022)
-
9.2.5 Global Glioblastoma Consumption and Growth Rate (2017-2022)
10 Global Cancer mTOR Inhibitors Market Outlook by Types and Applications to 2028
-
10.1 Global Cancer mTOR Inhibitors Consumption Forecast and Growth Rate by Type (2022-2028)
-
10.1.1 Global Afinitor/Votubia Consumption Forecast and Growth Rate (2022-2028)
-
10.1.2 Global Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Consumption Forecast and Growth Rate (2022-2028)
-
10.1.3 Global Torisel (Temsirolimus) Consumption Forecast and Growth Rate (2022-2028)
-
10.1.4 Global Evertor andndash Consumption Forecast and Growth Rate (2022-2028)
-
10.2 Global Cancer mTOR Inhibitors Consumption Forecast and Growth Rate by Application (2022-2028)
-
10.2.1 Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
10.2.2 Global Hematological Malignancy Consumption Forecast and Growth Rate (2022-2028)
-
10.2.3 Global Neuroendocrine Tumors Consumption Forecast and Growth Rate (2022-2028)
-
10.2.4 Global Hepatocellular Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
10.2.5 Global Glioblastoma Consumption Forecast and Growth Rate (2022-2028)
11 Global Cancer mTOR Inhibitors Import and Export Analysis (Top 5 Countries)
-
11.1 Global Cancer mTOR Inhibitors Import by Region (Top 5 Countries) (2017-2028)
-
11.2 Global Cancer mTOR Inhibitors Export by Region (Top 5 Countries) (2017-2028)
12 Coronavirus Disease (COVID-19) Impact
-
12.1 Industry Impact Analysis
-
12.2 Cancer mTOR Inhibitors Market Outlook to 2028 - COVID-19 Affected Forecasts
13 Competition Matrix
-
13.1 Target Markets
-
13.2 Comprehensive Analysis of Products in Competitive Markets
14 Global Cancer mTOR Inhibitors Market Competitive Analysis
-
14.1 HEC Pharm
-
14.1.1 HEC Pharm Company Details
-
14.1.2 HEC Pharm Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.1.3 HEC Pharm Cancer mTOR Inhibitors Product and Service
-
14.2 Takeda
-
14.2.1 Takeda Company Details
-
14.2.2 Takeda Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.2.3 Takeda Cancer mTOR Inhibitors Product and Service
-
14.3 Adimab
-
14.3.1 Adimab Company Details
-
14.3.2 Adimab Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.3.3 Adimab Cancer mTOR Inhibitors Product and Service
-
14.4 Intellikine
-
14.4.1 Intellikine Company Details
-
14.4.2 Intellikine Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.4.3 Intellikine Cancer mTOR Inhibitors Product and Service
-
14.5 Abraxis BioScience
-
14.5.1 Abraxis BioScience Company Details
-
14.5.2 Abraxis BioScience Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.5.3 Abraxis BioScience Cancer mTOR Inhibitors Product and Service
-
14.6 GlaxoSmithKline
-
14.6.1 GlaxoSmithKline Company Details
-
14.6.2 GlaxoSmithKline Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.6.3 GlaxoSmithKline Cancer mTOR Inhibitors Product and Service
-
14.7 Semafore Pharmaceuticals
-
14.7.1 Semafore Pharmaceuticals Company Details
-
14.7.2 Semafore Pharmaceuticals Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.7.3 Semafore Pharmaceuticals Cancer mTOR Inhibitors Product and Service
-
14.8 Wyeth
-
14.8.1 Wyeth Company Details
-
14.8.2 Wyeth Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.8.3 Wyeth Cancer mTOR Inhibitors Product and Service
-
14.9 Oneness Biotech
-
14.9.1 Oneness Biotech Company Details
-
14.9.2 Oneness Biotech Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.9.3 Oneness Biotech Cancer mTOR Inhibitors Product and Service
-
14.10 Eli Lilly
-
14.10.1 Eli Lilly Company Details
-
14.10.2 Eli Lilly Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.10.3 Eli Lilly Cancer mTOR Inhibitors Product and Service
-
14.11 Celator Pharmaceuticals
-
14.11.1 Celator Pharmaceuticals Company Details
-
14.11.2 Celator Pharmaceuticals Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.11.3 Celator Pharmaceuticals Cancer mTOR Inhibitors Product and Service
-
14.12 Novartis
-
14.12.1 Novartis Company Details
-
14.12.2 Novartis Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.12.3 Novartis Cancer mTOR Inhibitors Product and Service
-
14.13 Exelixis
-
14.13.1 Exelixis Company Details
-
14.13.2 Exelixis Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.13.3 Exelixis Cancer mTOR Inhibitors Product and Service
-
14.14 Celgene Corporation
-
14.14.1 Celgene Corporation Company Details
-
14.14.2 Celgene Corporation Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.14.3 Celgene Corporation Cancer mTOR Inhibitors Product and Service
-
14.15 PIQUR Therapeutics
-
14.15.1 PIQUR Therapeutics Company Details
-
14.15.2 PIQUR Therapeutics Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
14.15.3 PIQUR Therapeutics Cancer mTOR Inhibitors Product and Service
15 Appendix
TABLE OF CHARTS
-
Table Definition of Cancer mTOR Inhibitors
-
Figure Cancer mTOR Inhibitors Picture
-
Table Global Cancer mTOR Inhibitors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cancer mTOR Inhibitors Market Size and Forecast 2022 - 2028 (USD million)
-
Figure Global Cancer mTOR Inhibitors Market: Year-over-year Growth 2022 - 2028 (%)
-
Table Parent Market Analysis
-
Figure Parent Market Price
-
Table Related/Ancillary Market Outlook Analysis
-
Table Supplier Power Analysis
-
Table Buyer Power Analysis
-
Table Substitution Threat Analysis
-
Table Threat of New Entrants Analysis
-
Table Competitive Rivalry Analysis
-
Figure Global Cancer mTOR Inhibitors Consumption by Country (2017-2022)
-
Figure United States Cancer mTOR Inhibitors Consumption and Growth Rate (2017-2022)
-
Table Europe Cancer mTOR Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure China Cancer mTOR Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Japan Cancer mTOR Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure India Cancer mTOR Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure South Korea Cancer mTOR Inhibitors Consumption and Growth Rate (2017-2022)
-
Figure Global Cancer mTOR Inhibitors Consumption Forecast by Country (2022-2028)
-
Figure United States Cancer mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Cancer mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure China Cancer mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Cancer mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Cancer mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Cancer mTOR Inhibitors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Afinitor/Votubia Consumption and Growth Rate (2017-2022)
-
Figure Global Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Consumption and Growth Rate (2017-2022)
-
Figure Global Torisel (Temsirolimus) Consumption and Growth Rate (2017-2022)
-
Figure Global Evertor andndash Consumption and Growth Rate (2017-2022)
-
Figure Global Breast Cancer Consumption and Growth Rate (2017-2022)
-
Figure Global Hematological Malignancy Consumption and Growth Rate (2017-2022)
-
Figure Global Neuroendocrine Tumors Consumption and Growth Rate (2017-2022)
-
Figure Global Hepatocellular Carcinoma Consumption and Growth Rate (2017-2022)
-
Figure Global Glioblastoma Consumption and Growth Rate (2017-2022)
-
Figure Global Afinitor/Votubia Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Torisel (Temsirolimus) Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Evertor andndash Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Breast Cancer Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hematological Malignancy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Neuroendocrine Tumors Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Hepatocellular Carcinoma Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Glioblastoma Consumption Forecast and Growth Rate (2022-2028)
-
Table Global Cancer mTOR Inhibitors Import by Region (Top 5 Countries) (2017-2028)
-
Table Global Cancer mTOR Inhibitors Export by Region (Top 5 Countries) (2017-2028)
-
Table HEC Pharm (Foundation Year, Company Profile and etc.)
-
Table HEC Pharm Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table HEC Pharm Cancer mTOR Inhibitors Product and Service
-
Table Takeda (Foundation Year, Company Profile and etc.)
-
Table Takeda Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Takeda Cancer mTOR Inhibitors Product and Service
-
Table Adimab (Foundation Year, Company Profile and etc.)
-
Table Adimab Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Adimab Cancer mTOR Inhibitors Product and Service
-
Table Intellikine (Foundation Year, Company Profile and etc.)
-
Table Intellikine Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Intellikine Cancer mTOR Inhibitors Product and Service
-
Table Abraxis BioScience (Foundation Year, Company Profile and etc.)
-
Table Abraxis BioScience Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abraxis BioScience Cancer mTOR Inhibitors Product and Service
-
Table GlaxoSmithKline (Foundation Year, Company Profile and etc.)
-
Table GlaxoSmithKline Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline Cancer mTOR Inhibitors Product and Service
-
Table Semafore Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Semafore Pharmaceuticals Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Semafore Pharmaceuticals Cancer mTOR Inhibitors Product and Service
-
Table Wyeth (Foundation Year, Company Profile and etc.)
-
Table Wyeth Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Wyeth Cancer mTOR Inhibitors Product and Service
-
Table Oneness Biotech (Foundation Year, Company Profile and etc.)
-
Table Oneness Biotech Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Oneness Biotech Cancer mTOR Inhibitors Product and Service
-
Table Eli Lilly (Foundation Year, Company Profile and etc.)
-
Table Eli Lilly Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly Cancer mTOR Inhibitors Product and Service
-
Table Celator Pharmaceuticals (Foundation Year, Company Profile and etc.)
-
Table Celator Pharmaceuticals Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celator Pharmaceuticals Cancer mTOR Inhibitors Product and Service
-
Table Novartis (Foundation Year, Company Profile and etc.)
-
Table Novartis Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Novartis Cancer mTOR Inhibitors Product and Service
-
Table Exelixis (Foundation Year, Company Profile and etc.)
-
Table Exelixis Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Exelixis Cancer mTOR Inhibitors Product and Service
-
Table Celgene Corporation (Foundation Year, Company Profile and etc.)
-
Table Celgene Corporation Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table Celgene Corporation Cancer mTOR Inhibitors Product and Service
-
Table PIQUR Therapeutics (Foundation Year, Company Profile and etc.)
-
Table PIQUR Therapeutics Cancer mTOR Inhibitors Sales, Price, Value and Gross Profit (2017-2022)
-
Table PIQUR Therapeutics Cancer mTOR Inhibitors Product and Service
-
